# A Phase II Study of Anlotinib Combined With Penpulimab in Subjects With Gynecological Cancer

> **NCT05028504** · PHASE2 · UNKNOWN · sponsor: **Sichuan Cancer Hospital and Research Institute** · enrollment: 86 (estimated)

## Conditions studied

- Gynecological Cancer

## Interventions

- **DRUG:** Penpulimab
- **DRUG:** Anlotinib

## Key facts

- **NCT ID:** NCT05028504
- **Lead sponsor:** Sichuan Cancer Hospital and Research Institute
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2022-05-10
- **Primary completion:** 2024-12-31
- **Final completion:** 2025-12-31
- **Target enrollment:** 86 (ESTIMATED)
- **Last updated:** 2023-12-27


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05028504

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05028504, "A Phase II Study of Anlotinib Combined With Penpulimab in Subjects With Gynecological Cancer". Retrieved via AI Analytics 2026-06-04 from https://api.ai-analytics.org/clinical/NCT05028504. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*